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Abstract
Background: Monomeric Group IVB (Ti, Zr and Hf) metallocenes represent a new class of
antitumor compounds. There is literature on the general biological activities of some organotin
compounds. Unfortunately, there is little information with respect to the molecular level activity
of these organotin compounds. We recently started focusing on the anti-cancer activity of
organotin polymers that we had made for other purposes and as part of our platinum anti-cancer
effort.
Methods: For this study, we synthesized a new series of metallocene-containing compounds
coupling the metallocene unit with dienestrol, a synthetic, nonsteroidal estrogen. This is part of our
effort to couple known moieties that offer antitumor activity with biologically active units hoping
to increase the biological activity of the combination. The materials were confirmed to be
polymeric using light scattering photometry and the structural repeat unit was verified employing
matrix assisted laser desorption ionization mass spectrometry and infrared spectroscopy results.
Results: The polymers demonstrated the ability to suppress the growth of a series of tumor cell
lines originating from breast, colon, prostrate, and lung cancers at concentrations generally lower
than those required for inhibition of cell growth by the commonly used antitumor drug cisplatin.
Conclusion: These drugs show great promise in vitro against a number of cancer cell lines and
due to their polymeric nature will most likely be less toxic than currently used metal-containing
drugs such as cisplatin. These drugs also offer several addition positive aspects. First, the reactants
are commercially available so that additional synthetic steps are not needed. Second, synthesis of
the polymer is rapid, occurring within about 15 seconds. Third, the interfacial synthetic system is
already industrially employed in the synthesis of aromatic nylons and polycarbonates. Thus, the
ability to synthesize large amounts of the drugs is straight forward.
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Background
We have synthesized a number of condensation organo-
tin-containing polymers [1-12] and polymeric derivatives
of cisplatin [13-17] emphasizing biological activities.
Many of these have shown outstanding anticancer and
antiviral agents properties as well as the expected antibac-
terial properties. In some of these efforts we emphasized
the use of Lewis bases that themselves offered some bio-
logical activity including the known antiviral agent acyclo-
vir and a number of proven antibacterial agents such as
norfloxacin, ampicillin, tricarcillin, and ciprofloxacin.
Our overall rationale for employing known drugs coupled
with metal-containing moieties with characterized biolog-
ical effects is to create a unique compound that can inter-
act with the target (cancer, bacteria, virus) at several
venues. By targeting multiple sites the possibility that the
target will become resistant to the treatment is greatly
reduced increasing the effectiveness of the treatment.
The topic of metallocene polymers has been recently
reviewed [18]. We have described the synthesis and ability
to arrest the growth of various cells by a number of Group
IVB metallocene-containing polymers [1,19-21]. Recently
we described the synthesis of organotin polyethers
derived from diethylstilbestrol, DES, and the ability of
these polymers to arrest the growth of a number of cancer
cell lines.4 See Figure 1.
We also recently described the synthesis and ability to
arrest the growth of various cell lines for the analogous
polyethers derived from Group IVB metallocene dichlo-
rides.
Dienestrol,(4- [4-(hydroxyphenyl)hexa-2,4-dien-3-
yl]phenol, is one of the most widely utilized sex hor-
mones. It was initially synthesized in 1939 and initially
patented by both Boots and Hoffman-La Roche in 1949
[22,23]. In the popular literature it is often confused with
DES, diethylstilbestrol, but it is a distinct hormone with
its own chemical and biological properties. It is sold
under a variety of tradenames including Farmacyrol, Lipa-
mone, and Retalon-Oral.
Dienestrol is widely used in hormone therapy, mainly
hormone replace therapy or more precisely, estrogen
replacement therapy. See Figure 2.
Interestingly, little work has been done with respect to
incorporating dienestrol into polymers either through the
double bonds or through the diol moiety. Most of the cur-
rent efforts with respect to polymers involve the synthesis
of dienestrol, and similar drugs, employing covalent
molecular imprinting [24-29] Additional work has
focused on the controlled release of various steroids,
including dienestrol, from various polymeric matrices
[30-32]. See Figure 3.
In 1956 a patent described the synthesis of antienzymic
polymeric materials from the reaction of various diols
including dienestrol from reaction with phosphoric and
thiophosphoric acid [33]. It is not clear that any character-
ization of the product occurred since it was simply one of
about 30 diol, diamine, and alcohol-amine-containing
Lewis bases included in the patent.
More recently, we described the synthesis of various
polyphosphate and polyphosphate esters from the reac-
tion of phosphorous acid chlorides with dienestrol [34].
About three decades ago we initially synthesized metal-
locene polyethers including a number of polyethers con-
taining the titanocene, [35-37] zirconocene, [38] and
Repeat unit for the polymer from the reaction of DES and  diorganotin dihalides Figure 1
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hafnocene units [39]. This effort was recently reviewed
[18]. There were a number of reasons for our synthesis of
these materials including their use to control high energy
radiation, as permanent coloring agents, and as potential
anticancer agents [18]. Activity has recently increased in
the use of metallocene-containing compounds in the
treatment of cancer [40-52]. Much of this effort has
focused on the use of titanocene-containing compounds.
See Figure 4.
Here we describe the synthesis of Group IVB metallocene
polyethers based on the reaction of the Group IVB metal-
locene dichloride and dienestrol (Figure 5) and prelimi-
nary results with respect to their ability to arrest the
growth of selected cancer cell lines. The advantages of
employing polymeric drugs has been recently reviewed
[16,53-55].
Methods
Synthesis and Physical Characterization
Polymerization was accomplished employing the classical
or aqueous interfacial polycondensation system. Briefly,
an aqueous solution (30 mL) containing the dienestrol
(0.00300 mol) and sodium hydroxide (0.0060 mole) was
transferred to a one quart Kimax emulsifying jar fitted on
top of a Waring Blender (model 1120; no load speed of
about 18,000 rpm; reactions were carried out at about
25°C). Stirring was begun and a chloroform solution (30
ml) containing the metallocene dihalide (0.00300 mol)
was rapidly added (about 3-4 seconds) through a hole in
the jar lid using a powder funnel. The resulting solution
was blended for 15 seconds. The precipitate was recovered
using vacuum filtration and washed several times with
deionized water and chloroform to remove unreacted
materials and unwanted by-products. The solid was
washed onto a glass petri dish and allowed to dry at room
temperature.
Chain length was determined employing light scattering
photometry using a Brice-Phoenix BP 3000 Universal
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Repeat unit for the polymer from the reaction of dienestrol  and zirconocene dichloride, M = Zr Figure 5
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Light Scattering Photometer. Refractive indicies were
obtained using a Bauch & Lomb Model 3-L refractometer.
FTIR spectra were obtained employing KBr pellets using a
Mattson Instruments galaxy Series 4020 FTIR using 32
scans and an instrumental resolution of 4 cm-1.
High resolution electron impact positive ion matrix
assisted laser desorption ionization time of flight, HR
MALDI-TOF, mass spectrometry was carried out employ-
ing a Voyager-DE STR BioSpectrometer, Applied Biosys-
tems, Foster City, CA. The standard settings were used
with a linear mode of operation and an accelerating volt-
age of 25,000 volts; grid voltage 90% and an acquisition
mass range of 100 to 2,000 daltons. Two hundred shots
were typically taken for each spectrum. Several matrix
materials were employed but here only results employing
α-cyano-4-hydroxycinnamic acid are included for the haf-
nocene and zirconocene products and the matrix 2,5-
dihydroxybenzoic acid for the titanocene product.
Biological Characterization
Each of the cell lines listed in Table 1 were obtained from
NCI or ATCC and maintained in MEM supplemented
with 10% fetal bovine serum at 37°C in a 5% carbon
dioxide atmosphere.
For testing of the compounds, cells were harvested,
counted, and plated into 96-well plates at 1 × 104 cells per
well in MEM-Eagles supplemented with 10% fetal bovine
serum, and incubated for 24 hours at 37°C in a 5% car-
bon dioxide atmosphere. A stock solution of the com-
pound was prepared in DMSO at a known concentration.
On day two 100 μL MEM-Eagles supplemented with 10%
fetal bovine serum and the indicated drug concentrations
was added. Seventy-two hours later the cells were assayed
for proliferation using the CellTiter 96® Aqueous One
Solution Cell Proliferation Assay by Promega Corpora-
tion. The assay is a colorimetric method for determining
the number of viable cells in proliferation, cytotoxicity or
chemosensitivity assays. The assay solution contains a
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-
zolium, inner salt; MTS(a)] and an electron coupling rea-
gent (phenazine ethosulfate; PES). Assays are performed
by adding a small amount of the CellTiter 96 Aqueous
One Solution Reagent directly to culture wells, incubating
for 1-4 hours and then recording absorbance at 490 nm
with a 96-well plate reader. The quantity of formazan
product as measured by the amount of 490 nm absorb-
ance is directly proportional to the number of living cells
in culture.
All cytotoxicity values are calculated against a base-line
value for each line that was generated from "mock-treat-
ment" of the normal and tumor cells lines with media
supplemented with all diluents used to prepare the chem-
otherapeutic compounds. For example, if the compounds
were dissolved in DMSO and serial dilutions prepared in
MEM to treat the cells, then the mock-treated cells were
"treated" with the same serial dilutions of DMSO without
added chemotherapeutic compound. This was done to
ensure that any cytotoxicity observed was due to the activ-
ity of the compound and not the diluents. For the studies
reported here, the mock-treatment never resulted in a loss
of cell viability of more than one percent, demonstrating
that the activity observed was not due to cytotoxicity of
any of the diluents used, but was due to activity of the
tested compounds.
Results and Discussion
Synthesis and Structural Characterization
The products were synthesized in average yields in the
same range as found for the synthesis of the analogous
products except employing DES as the diol in place of
dienestrol (Table 1).
The polymers are not soluble in DMF, acetone, and DMF,
all solvents that typically dissolved other similar organo-
metallic condensation polymers, and only partially solu-
ble in DMSO. In comparison to the analogous organotin-
diethylstilbestrol products, the Group IVB metallocene
products have poorer solubilities. This trend is found for
other polymers synthesized by us where the metallocene-
containing polymers exhibit poor solubility in compari-
son to the analogous organotin polymers.17 The products
are soluble in HMPA. Results appear in Table 1. The prod-
ucts are medium to long chained products.
The products from titanocene and zirconocene are stable
in HMPA solution for three months whereas the
hanfocene product was stable for 2 months and at month
three there was a modest loss in molecular weight from
2.1 × 105 to 1.7 × 105.
Infrared spectral results are consistent with the proposed
repeat unit. Only selected bands will be described here.
Here we will concentrate on the IR spectra from the
titanocene product. The dienestrol-associated O-H stretch
occurs with a maximum at 3415 (all bands given in cm-1).
Table 1: Product yield and molecular weight as a function of 
metallocene.
Metallocene % Yield dn/dc Mw DP
Titanocene 43 -3.5 3.3 × 107 70,000
Zirconocene 42 -1.0 6.7 × 106 14,000
Hafnocene 47 -0.40 2.1 × 105 400
Note. While the solubility in DMSO is too low to permit NMR and 
LS in DMSO it is sufficient to allow for biological testing employing 
DMSO stock solution.BMC Cancer 2009, 9:358 http://www.biomedcentral.com/1471-2407/9/358
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It is the most intense band in the spectrum of dienestrol.
Dienestrol shows bands due to the aromatic C-H at 3026
and 3005 and aliphatic C-H bands at 2972, 2933, 2910,
and 2852. Titanocene dichloride shows a band at 3103
assigned to C-H aromatic stretching. The product shows
bands at about 3100, 3027, 3005, 2972, 2910, and 2854.
The locations of bands associated with the Ti-O are
reported to be about 345 for the symmetric stretch and
420 for the asymmetric stretch. The presence of a new
band at 440 is assigned to the Ti-O asymmetric stretch.
The 345 band is below the capability of the employed
instrument. Other titanocene dichloride, dienestrol, and
metallocene polymer-associated bands and assignments
are given in Table 2. Thus, IR spectral results are consistent
with the proposed structure.
A modified MALDI MS analysis was carried out on the
products and reactants [55,56] The most intense ion frag-
ment for dienestrol itself was found at 265 (all ion frag-
ments are given in m/z or m/e = 1 in Daltons) assigned to
dienestrol. The next intense was at 212 assigned to
dienestrol minus 2 C2H4.
For brevity, only the results for the titanocene products
will be described. Table 3 contains the ion fragments and
ion fragment clusters found for the product of titanocene
dichloride and dienestrol in the range of 100 to 1,000 dal-
tons.
A number of abbreviations are employed to describe the
possible ion fragment structures. Some of these are
described in Figure 6 below. Additional ones are U = one
units; 2 U = 2 units, D = dienestrol, Me = methylene, and
Ph = phenylene.
There is some loss of the cyclopentadienyl, Cp, group.
This is not unexpected in light of other MS studies that
show that metallocene associated Cp groups are especially
sensitive to removal from the metallocene moieties [18].
Titanium has five isotopes. This allows isotopic abun-
dance matches to be made. Table 4 contains the isotopic
matches for two of these ion fragment clusters. The abun-
dance matches are reasonable and consistent with the
presence of one titanium in each ion fragment cluster.
Table 5 contains the ion fragment clusters found in the
range of 10,000 to about 150,000 along with possible
assignments. These assignments are to be viewed as sug-
gestive only. This is particularly true because of the ready
removal of the Cp group. In other cases such removals
occur at only the sites of bond scission so the loss of one
or two Cp groups is believed to be typical.
The presence of these high mass ion fragments is consist-
ent with the polymeric nature of the tested material. A
number of these ion fragments may be entire chains such
as those at 17068, 21940, 22219, 28310, 49238, 56009,
88777, and 142044 consistent with the "soft" nature of
MALDI MS.
The results are consistent with other studies where chain
scission occurs mainly at the heteroatoms. They are also
consistent with the assigned product structure.
Table 2: Vibrational band assignments for titanocene dichloride and the products of Group IVB metallocene dichlorides and 
dienestrol
Mode Dien Cp2TiCl2 Ti-Polymer Zr-Polymer Hf-polymer
OH Stretch 3415
CH St. Ar 3026,3005 3103 3100,3027, 3091 3100, 3027, 3005 3069, 3029, 3005
CH St. Alip 2972, 2933, 2910, 2852 2972, 2910, 2852 2970, 2912, 2854 2970, 2912, 2866
C = C St. Alip 1641 1651 1650 1650
C = C St. Ar 1603 1608 1604 1606
Phenylene Ske 1504 1500 1506 1501
(Cp) CC St 1440 1425 1423 1426
C-O St 1419 1389 1390 1425
CC Stretch 1364 1330 1331 1333
CH i.p. Bend 1238 1243 1244 1246
Ring Breathing 1166 1171 1171 1171
CH o.p. Bend 1093 1099 1099 1101
C-C St 1062 1040 1040 1040
CH i.p. Bend 1015 1012 1014 1014
CC i.p. Bend 949 956 952 955
CH o.p. Bend 892 902 900 854
CH o.p. Bend 820 829 827 828
CH2 Rocking 740 740 740 721
CC o.p. Bend 613 617 619 619BMC Cancer 2009, 9:358 http://www.biomedcentral.com/1471-2407/9/358
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Cell Line Results
The tested cell lines represent a wide range of cancers
including breast, lung, colon, and prostate cancer cell
lines (Table 6). They also include two "normal" cell lines,
the WI-38 human cells which are typically employed as a
normal cell line in such studies, and 3T3 cells that are
mouse cells that are partially transformed. Both of these
cell lines are often employed as examples of healthy cell
lines and the results from them are compared to results
from the various cancer cell lines giving measures of the
ability of the tested drug to differentiate between healthy
and cancer cell lines. Of the two, the WI-38 is more widely
employed as representative of a healthy cell line for such
comparisons. Also included in the test samples is cispla-
tin, a widely employed anticancer drug, as a comparison
to a known anticancer agent.
Different measures are employed in the evaluation of cell
line results. Here we use the two most widely employed-
GI50  values which is the lowest concentration where
growth is inhibited by 50% and the Chemotherapeutic
Index, CI50 which is a measure of the amount needed to
inhibit 50% cell growth, GI50, for the normal cell lines,
here WI-38 and 3T3 cell lines, divided by the amount
needed to inhibit 50% cell growth for one of the cancer
cell lines. It is to be noted that different researchers gener-
ally emphasize one of these measures over the other with
neither measure universally accepted. Thus, results from
both of these measures are presented. [see Additional file
1: Table S1] contains the GI50 values for the polymers,
DES, and cisplatin.
The GI50 values for the polymers are significantly lower
than for cisplatin with the exception of the WI-38 healthy
cells. The GI50 values for the metallocene monomers are
much higher than for the analogous polymers. They are in
the general range of the dienestrol itself. Further, with
respect to the polymers the breast cancer cell line without
estrogen (MDA MB-231) showed better test results than
the breast cancer cell line that is positive for estrogen
(MCF-7) perhaps because some of the drug is bound to
the estrogen receptors and not available to act within the
cell. This is consistent with the finding that DES is effec-
tive against estrogen receptor positive (ER+) tumors
[57,58].
The second measure is the 50% chemotherapeutic index,
CI50. When describing the CI some researchers employ the
similar terms ED or effective dose in place of the GI value
for the cancer cells and LD or lethal dose in place of GI for
the healthy cell line, here the WI-38 cell line. Thus, CI50 =
LD50/ED50. Larger values are desired since they indicate
that a larger concentration is required to inhibit the
healthy cells in comparison to the cancer cells or stated in
another way, larger values indicate some preference for
inhibiting the cancer cells in preference to the normal
cells. In general, CI50 values larger than 2 are considered
Table 3: Most abundant ion fragment clusters for the product from titanocene dichloride and dienestrol; 100 to 1,000 Da.
m/e (Proposed) Assignment m/e (Proposed) Assignment
129 CpTiO 193 Cp2TiO
266 D 289 D, Na
313 U-A 529 U+A, O-Cp
551 U+B-Cp 573 U+B
643 U+Cp2TiO 706 U+D
Fragmentation of dienestrol moiety for MALDI MS fragmen- tation identification Figure 6







R        A
  B
Table 4: Isotopic abundance matches for ion fragment clusters 
centering about 529 and 551 daltons.
U+A, O-Cp U+B-Cp
m/e % Nat Abu m/e % Rel Abun m/e % Rel Abu
4 61 15 2 71 15 4 9 1 2
4 71 05 2 81 05 5 0 1 1
48 100 529 100 551 100
49 7 530 7 552 8
50 7 531 5 553 7BMC Cancer 2009, 9:358 http://www.biomedcentral.com/1471-2407/9/358
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significant. CI50 values are given in [see Additional file 2:
Table S2].
An additional question concerns the influence of simply
having the metallocene moiety present in a polymer. [see
Additional file 3: Table S3] contains the CI50 values nor-
malized against the CI50 value for dienestrol. This ratio
may offer some measure of the effectiveness of having the
two monomer moieties within the polymer. Values
greater than one would be consistent with the presence of
that moiety present in the polymer having a favorable
effect.
Conclusion
Several features are apparent. First, cisplatin, while a most
widely employed anticancer drug, has small CI50 values,
all 0.02 and lower. Second, the metallocene dichlorides
all have low CI50 values. Third, dienestrol has two CI50 val-
ues greater than two. Thus, it shows some significant abil-
ity to inhibit the cell growth of the transformed, 3T3, and
one cancer drug in comparison to the concentration
where the healthy WI-38 cell line is not affected. Third, the
metallocene polymers all exhibit some CI50 values above
2. The hafnocene and zironocene-dienestrol polymers
exhibit high CI50 values for all of the tested cancer and
transformed cell lines. This is consistent with these partic-
ular polymers meriting further study. Further, while much
of the recent anticancer effort with respect to metallocene-
containing compounds has focused on titanocene-con-
taining compounds, the zirconocene and hafnocene pol-
ymers showed somewhat better CI50 values in the current
study. Thus, future studies might consider not only the
titanocene-containing compounds but also the analogous
zirconocene and hafnocene compounds for study. Fourth,
while the dienestrol exhibited decent CI50 values, all of the
corresponding polymers exhibited higher CI50 values for
all of the cell lines. Thus, the ability to arrest cell growth is
not only dependent on the presence of the dienestrol but
also on the presence of the metallocene moiety.
With respect to the normalization of the CI50 values for
each cell line against the CI50 values for dienestrol itself,
no norm has been established for this kind of compari-
son. Thus, conclusions should be viewed in this light. All
of the values for the polymers are greater than two consist-
ent with the presence of having the combination of
dienestrol and metallocene in the same polymer being
positive with respect to the ability to inhibit cancer and
transformed cells in comparison to the healthy WI-38 cell
line.
The current drugs also offer several addition positive
aspects. First, the reactants are commercially available so
that additional synthetic steps are not needed. Second,
Table 5: MALDI MS Results for the mass range of 10,000 to 160,000 Da for the product of titanocene dichloride and dienestrol.
m/e (Possible) Assignment m/e (Possible) Assignment
10823 24U+Cp2TiO 11172 25U+B-Cp
11568 26U+A-Cp 13070 30U-Cp2TiO
15692 35U+Cp2TiO 16750 38U-Cp
17068 39U-Cp2Ti 21940 50U-Cp2Ti
22219 50U+A-OMe 28310 64U
28863 65U+Cp2Ti 32027 72U+Cp2Ti
38381 87U-OPh 44590 101U-OPh
48138 109U-OPh 49238 111U-A
49569 112U+O 56009 127U-Cp2Ti
56959 129U-O 59220 134U-Cp
67201 152U-Cp+O 84377 191U-2Cp+O
88777 201U-A 94899 214U+D-O
116850 264U+A-Cp 130742 296U-Cp2TiO
141309 319U+Cp2TiO 142044 321U
154454 349U+A-Cp
Table 6: Cell line Characteristics and Identification
Strain NCI/ATCC designation Species Tumor orgin Histological type
3465 PC-3 Human Prostate Carcinoma
7233 MDA MB-231 Human Breast pleural effusion Adenocarcinoma
1507 HT-29 Human Colon recto-sigmoid Adenocarcinoma
7259 MCF-7 Human Breast pleural effusion Adenocarcinoma
CCL-75 WI-38 Human Lung normal embryonic Fibroblast
CRL-1658 NIH 3T3 Mouse Continuous cell line of highly contact-inhibited cells Embryo-fibroblastBMC Cancer 2009, 9:358 http://www.biomedcentral.com/1471-2407/9/358
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synthesis of the polymer is rapid, occurring within about
15 seconds. Third, the interfacial synthetic system is
already industrially employed in the synthesis of aromatic
nylons and polycarbonates. Thus, the ability to synthesize
large amounts of the drugs is straight forward.
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